EUCTR2010-023494-19-SE进行中（未招募）1 期
A Phase IIa, Multi-Centre, Double-blind, Randomised, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of K(D)PT after Multiple Ascending Doses in Patients with Active Mild to Moderate Ulcerative Colitis
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Provision of signed, dated and written informed consent prior to any study specific procedures.
- •2. Adult males/females aged 18 to 70 years inclusive.
- •3. Have a body mass index (BMI) =18 and =35 kg/m2.
- •4. Females must have a negative pregnancy test at screening and on admission to the unit.
- •5. Females of child-bearing potential must agree to use medically acceptable methods of contraception.
- •6. Females of non-child-bearing potential should fulfil either of the following criteria at screening:
- •- post menopausal defined as amenorrhoea for greater than 1 year following cessation of all exogenous hormonal treatments and with follicle stimulating hormone (FSH) and luteinising hormone (LH) in the laboratory defined post-menopausal range
- •- documentation of irreversible surgical sterilisation by bilateral oophorectomy, bilateral salpingectomy and hysterectomy but not tubal ligation.
- •7. Male patients must avoid fathering.
- •8. Mild to moderate active ulcerative colitis confirmed by a CAI between 4 and 9.
- •9. No pre-treatment of active ulcerative colitis except for:
- •- stable dose of mesalazine, sulfasalazine or olsalazine in the usual maintenance dose for >4 weeks before time of consent (the medication may be optimised [and administered via the oral or rectal route] by a referring gastroenterologist just before the patient enters the study, i.e within 5 days of first dose of IMP but not after first dose)
- •- stable dose of azathioprine or mercaptopurine in the usual maintenance dose for >4 weeks before time of consent (the medication may be optimised [and administered via the oral or rectal route] by a referring gastroenterologist just before the patient enters the study, i.e within 5 days of first dose of IMP but not after first dose).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Previous participation in any clinical study with K(D)PT.
- •2. Morbus Crohn.
- •3. Any clinically relevant abnormal findings in physical examination or clinical laboratory tests (clinical chemistry, haematology, urinalysis, coagulation) at screening, vital signs (supine blood pressure and heart rate) or ECG pre-dose Day 1, which, in the opinion of the Investigator, may put the patient at risk because of his/her participation in the study.
- •4. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study or influence the results or the patient’s ability to participate in the study.
- •5. History of bleeding disturbance or thrombotic disorder.
- •6. History of or current alcohol or drug abuse, as judged by the Investigator.
- •7. Participation in another investigational drug study within 3 months before first administration of IMP or participation in a method development study (no drug) 1 month prior to first administration of IMP (Note: participation is identified as the completion of a treatment-related visit).
- •8. Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks prior to the first administration of IMP.
- •9. Donation of blood within 3 months, or donation of plasma within 14 days, prior to first administration of IMP.
- •10. Other pre-treatment of ulcerative colitis than mesalazine, sulfasalazine, olsalazine, azathioprine or mercaptopurine.
- •11. Proctosigmoiditis (less than 25 cm).
- •12. Use of antibiotics within 6 weeks prior to first administration of IMP.
- •13. Previous anti-TNF therapy.
- •14. Marcumarisation or moderate to severe grade coagulation defects as judged by the Investigator.
- •15. Haemoglobin (Hb) value below 100 g/L (females) or 110 g/L (males).
- •16. QTcF >450 ms or <350 ms or QT >500 ms or other ECG abnormality making interpretation more difficult as judged by the Investigator.
- •17. A definite or suspected personal history of intolerance or hypersensitivity to drugs and/or their excipients, judged to be clinically relevant by the Investigator.
- •18. Significant hypersensitivity or allergy, as judged by the Investigator.
- •19. Allergy against methylparaben or propylparaben.
- •20. Positive results on screening tests for hepatitis B and/or C and/or human immunodeficiency virus (HIV).
- •21. Positive result on screening tests for drugs of abuse at screening.
- •22. Positive screen for alcohol breath test at screening/admission to the unit.
- •23. Positive stool result for any of the enteric pathogens: Clostridium, Salmonella, Shigella, Campilobacter or Yersinia.
- •24. Involvement in the planning and conduct of the study.
- •25. Planned in-patient surgery, dental procedure or hospitalisation during the study.
- •26. Patients who in the opinion of the Investigator should not participate in the study.
- •27. Patients who are unwilling or unable to participate in the study.
研究者
相似试验
进行中（未招募）
1 期
A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group, 12-Month Treatment, Adaptive Design Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD3241 in Patients with Multiple System AtrophyMedDRA version: 12.1Level: LLTClassification code 10064060Term: Multiple system atrophyMultiple system atrophyEUCTR2009-018157-23-ATAstraZeneca AB120
进行中（未招募）
不适用
A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group 12-Month Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD3241 in Patients with Multiple System AtrophyEstudio de fase IIa, multicéntrico, doble ciego, aleatorizado, controlado con placebo, de gruposparalelos, de 12 meses de duración para evaluar la eficacia, la seguridad, la tolerabilidad y lafarmacocinética de AZD3241 en pacientes con atrofia multisistémicaEUCTR2009-018157-23-ESAstraZeneca AB110
进行中（未招募）
不适用
A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group 12-Month Treatment, Adaptive Design Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD3241 in Patients with Multiple System AtrophyMultiple system atrophyMedDRA version: 12.1Level: LLTClassification code 10064060Term: Multiple system atrophyEUCTR2009-018157-23-GBAstraZeneca AB135
进行中（未招募）
不适用
A Phase IIa, Multi-Center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DNB-001 in Patients with Angina Pectoris and Moderate Chronic Kidney Disease Undergoing Percutaneous Coronary InterventioEUCTR2007-002208-17-NLDanube Pharmaceuticals60
进行中（未招募）
不适用
PET study in PD patientsMicroglia activation as measured by [11C]PBR28 binding to TSPOMedDRA version: 14.1Level: LLTClassification code 10013113Term: Disease Parkinson'sSystem Organ Class: 10029205 - Nervous system disordersParkinson's DiseaseEUCTR2011-004803-19-FIAstraZeneca AB24